FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,276 letters match. Newest first.

  1. Amneal Pharmaceuticals, LLC

    FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.

    High risk
  2. Green Vitality dba Gr33n

    FDA warned Green Vitality dba Gr33n that its Jimerito Honey Eye Drops are an unapproved new drug sold with disease-treatment claims.

    High risk
  3. My Holistic Honey c/o Shenzhen Qanhai Wanb Express Supply Chain Co., LTD

    FDA warned My Holistic Honey that its honey eye drops are an unapproved new drug sold with drug claims.

    High risk
  4. Homeopathic Educational Services dba Homeopathic Family Medicine

    FDA says Homeopathic Family Medicine sells unapproved Cineraria Maritima Eye Drops for cataracts online.

    High risk
  5. Mel Honey US

    FDA warned Mel Honey US that its Jimerito (Melipona) Honey eye drops are an unapproved new drug.

    High risk
  6. Supply Center USA

    Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.

    High risk
  7. Trew Balance

    FDA warned Trew Balance that its Trew Vision CBD Eye Drops are an unapproved new drug sold with disease-treatment claims.

    High risk
  8. Life Enthusiast Co-op

    FDA tells Life Enthusiast Co-op its three eye products sold online are unapproved new drugs.

    High risk
  9. Wisconsin Pharmacal Company, LLC

    FDA warns Wisconsin Pharmacal over OTC drug manufacturing violations, including released rejected product and S. aureus contamination.

    High risk
  10. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  11. AlzClipp / UniUni

    FDA warns AlzClipp/UniUni that its AlzClipp nasal product is an unapproved new drug and misbranded with false FDA approval claims.

    High risk
  12. Anhui Hanbon Daily Chemical Co., Ltd.

    FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.

    High risk
  13. Everlaan Organics, Inc. dba Maple Organics

    FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.

    High risk
  14. www.usaquickmeds.com

    FDA warned usaquickmeds.com for selling unapproved and misbranded opioids and benzodiazepines online without prescriptions.

    High risk
  15. ABBE Laboratories, Inc.

    FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.

    High risk
  16. Vacation Inc.

    FDA warned Vacation Inc. that its whipped-cream-style sunscreen mousses are unapproved drugs and that their food-like cans are misleading.

    High risk
  17. Kalani AB dba Kalani Sunwear

    FDA warns Kalani AB that its Sun Mousse SPF 50 sunscreen is an unapproved, misbranded drug for US sale.

    High risk
  18. K & Care Organics

    FDA warns K & Care Organics over unapproved over-the-counter (OTC) foam sunscreen drugs sold in the U.S. without required authorization.

    High risk
  19. Fallien Cosmeceuticals Ltd. dba Fallene Ltd.

    FDA warns Fallien over unapproved OTC sunscreen foam TiZO SHEERFOAM SPF 30 sold without required authorization.

    Medium
  20. Supergoop!

    FDA warned Supergoop! that its over-the-counter sunscreen body mousse is illegally labeled because foam dosage forms are not allowed under the sunscreen monograph.

    Medium
  21. Confer With

    FDA told London-based Confer With that its Vivant True Tone skin-lightening serum is an unapproved drug sold without FDA approval.

    High risk
  22. Gussyup LLC dba Private Label Grooming

    FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.

    High risk
  23. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  24. Shiva Analyticals Private Limited

    FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.

    High risk
  25. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  26. www.mysteroidsmarket.com

    FDA warns Israel-based website mysteroidsmarket.com for selling unapproved and misbranded stimulants and benzodiazepines to U.S. consumers.

    High risk
  27. www.d-pharmacy.com

    FDA warned Singapore website d-pharmacy.com for selling unapproved prescription opioids, benzodiazepines, and stimulants to U.S. consumers.

    High risk
  28. www.portmeds.com

    FDA warned www.portmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants online without prescriptions.

    High risk
  29. www.plakini-pharma.com

    FDA warned Malaysia-based website plakini-pharma.com for selling unapproved, misbranded opioids, benzodiazepines, and stimulants to U.S. consumers.

    High risk
  30. Macsen Drugs

    FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.

    High risk
  31. Glenmark Pharmaceuticals Limited

    FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.

    High risk
  32. Medical Chemical Corporation

    FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.

    High risk
  33. Nature’s Fusions LLC

    FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.

    High risk
  34. Covalent Medical

    FDA warned Covalent Medical that its FOCUS PI post-injection eye drops are an unapproved new drug with claims not allowed for over-the-counter eye products.

    Medium
  35. Scope Health Inc

    FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.

    High risk
  36. Revitalize Energy, Inc.

    FDA warned Revitalize Energy that its Revitalize Energizing Eye Drops are an unapproved new drug and misbranded.

    High risk
  37. Thea Pharma, Inc.

    FDA warns Thea Pharma that IVIZIA OTC lubricant eye drops are an unapproved and misbranded new drug.

    High risk
  38. EyeTech One, LLC

    FDA warns EyeTech One that its EYELIVIO lubricant eye ointment is an unapproved new drug and misbranded.

    Medium
  39. Daewoo Pharmaceutical Co., Ltd.

    FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.

    High risk
  40. Mark J. Savant, M.D

    FDA warns clinical investigator Mark J. Savant, M.D., over protocol dosing and eligibility failures and missing informed consent in a drug trial.

    High risk
  41. 7Tabz Retail, LLC

    FDA says 7Tabz Retail sells unapproved 7-OH drug products online with drug-like claims.

    High risk
  42. Libby Laboratories, Inc.

    FDA warned Libby Laboratories of Berkeley, California, that its drug manufacturing violated CGMP, including releasing a hospital antiseptic without microbial testing.

    High risk
  43. Xtreme Tools International, Inc.

    FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.

    High risk
  44. Dynamic Blending Specialists, Inc.

    FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.

    High risk
  45. Exela Pharma Sciences, LLC

    Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.

    High risk
  46. Peter Michael, M.D.

    FDA warns clinical investigator Peter Michael, M.D. that pediatric trial subjects received twice the protocol's maximum drug dose.

    High risk
  47. www.buynetmeds.com

    FDA warned www.buynetmeds.com for selling unapproved, misbranded tapentadol and semaglutide drugs, including injectables, to U.S. consumers online.

    High risk
  48. Healwell Homeo Private Limited

    FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.

    High risk
  49. Staska Pharmaceuticals, Inc.

    FDA warns Staska Pharmaceuticals, a Nebraska outsourcing facility, that sterile compounded drugs had contamination risks and labeling problems.

    High risk
  50. Pushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi

    FDA warns Turkish OTC drug wipe maker Pushclean over missing finished-product and component testing.

    High risk